RecruitingNot ApplicableNCT06847932

Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development

Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development: a Randomized Control Trial

Sponsor

National Defense Medical Center, Taiwan

Enrollment

14,726 participants

Start Date

Jul 1, 2025

Study Type

INTERVENTIONAL

Conditions

Artificial Intelligence (AI)Atrial Fibrillation (AF)Electrocardiogram Premature Atrial Complexes Atrial Arrhythmias

Summary

Our study aimed to use an AF-predict AI-ECG alert system to help physicians identify patients who need to wear a continuous cardiac rhythm monitor for new diagnoses of atrial fibrillation (AF), atrial flutter (AFL), or atrial arrhythmia with high AF risk, including premature atrial complexes (PAC) ≥ 500/24hr, burst PACs \> 20 beats, non-sustained AF/AFL.

Eligibility

Min Age: 40 DaysMax Age: 85 Days

Plain Language Summary

Simplified for easier understanding

This trial is testing whether AI-powered ECG (heart tracing) technology can alert doctors early when a patient is at risk of developing atrial fibrillation (an irregular heartbeat), so it can be treated before it causes a stroke or other complications. You may be eligible if: you are a patient being seen in an inpatient or outpatient department; and you have had at least one ECG in the past year. You may NOT be eligible if: you have already been diagnosed with atrial fibrillation; you have had a procedure to treat it (ablation); you have a pacemaker or implanted heart device; or you are currently taking certain heart rhythm or blood-thinning medications. Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.